neoBona the new generation of non-invasive prenatal screening test (NIPT)
Available options
neoBona is a state-of-the-art NIPT test that provides highly reliable results for screening for:
- Most common chromosomal aneuploidies (21, 18 & 13)
- Sex chromosome aneuploidies and fetal sex
neoBona GenomeWide provides the most comprehensive view of the fetal genome by analysing all 23 pairs of chromosomes to expand the screening to other rare chromosomal abnormalities1 by additionally assessing the presence of:
- Rare autosomal trisomies1 (RAT, for all autosomes other than 21,18,13)
- Structural anomalies2 (large or small deletions or duplications greater than or equal to 7 Mb, on all the autosomes)
1 Associated with miscarriage, malformation, fetal anomalies and developmental and/or growth delays.
2 Partial loss or gain of chromosomal regions, also known as CNV (copy-number variants)
SINGLE PREGNANCY
- Trisomies 21, 18 and 13
- Fetal sex (optional, where permitted)
- Sex chromosome aneuploidies + fetal sex (optional)
TWIN PREGNANCIES
- Trisomies 21, 18 and 13
- Determination of the presence of Y chromosome (optional)
RESULTS
MAXIMUM 5 WORKING DAYS
SINGLE PREGNANCY
- Trisomies 21, 18 and 13
- Fetal sex (optional, where permitted)
- Sex chromosome aneuploidies + fetal sex
- On all autosomal chromosomes (non-sex chromosomes):
- Aneuploidies
- Duplications/deletions (CNVs) greater than or equal to 7 Mb in size
TWIN PREGNANCIES
- Trisomies 21, 18 and 13
- Determination of the presence of Y chromosome
- On all autosomal chromosomes (non-sex chromosomes):
- Aneuploidies
- Duplications/deletions (CNVs) greater than or equal to 7 Mb in size
RESULTS
MAXIMUM 5 WORKING DAYS
For all types of pregnancies: 1 or 2 fetuses, IVF, sperm or egg donation, vanishing or non-evolving fetus. Both neoBona options combine reliability and excellent performance to offer the most accurate screening, neoBona can be performed from 10 weeks of pregnancy (10+0 after LMP) until term, from a single blood sample. For more information, please contact the laboratory.
Advantages of neoBona
More advanced and accurate technology
The bidirectional (WGS paired-end) massive genome sequencing technology allows the determination of the length of placental cfDNA in a fast and efficient way. As such cfDNA fragments are shorter than those of maternal origin, this innovative technology makes it possible to differentiate between the two and focus on the analysis of the short fragments (mostly placental). The result is improved sensitivity and specificity even when the fetal fraction is low, increasing the probabilty of obtaining a reliable result notably in challenging situations including aneuploidy, post-IVF, and/or high maternal BMI.
FETAL FRACTION
Paired-end sequencing combined with the advanced bioinformatic algorithms including other sequencing parameters allow determination of the fetal fraction (FF) and a reliable result even with low FF, minimizing the number of patients requiring a new blood sample (>99% of samples reported directly, without the need for repeated blood sampling).
EXPERTISE AND TECHNOLOGY AT YOUR SERVICE
SYNLAB was a pioneer in the introduction of non-invasive prenatal genetic testing in Europe and particularly of the implementation of the genome-wide paired-end technology in NIPT in 2015, in collaboration with Illumina, a world leader in DNA sequencing.
SYNLAB supports you, the clinician, with access to genetic counselling, expert consultation and interpretation for neoBona from our genetic experts, as well as a full range of services including advanced geentic testing (prenatal or postnatal) and a complete portfolio of laboratory diagnostics.
NEOBONA QUALITY ASSURANCE
The neoBona test was codeveloped with illumina and validated and published by SYNLAB with Prof. Nicolaides (Cirigliano et al 2017).
The neoBona laboratory test and analysis software are fully IVDR*-certified for patient testing and neoBona is performed exclusively in ISO 15189*-accredited expert centres in the European Union. All neoBona testing laboratories perform annual external quality assessment with the European Molecular Quality Network (EMQN).
Genetic data from the neoBona test is securely stored inside our expert centres in the European Union. Your patients' samples and data are used exclusively for the requested test, and never shared for other reasons.
*IVDR is the latest European Union (EU) regulatory legislation for ensuring that medical laboratory tests provide a high level of patient safety, product quality, and transparency.
*ISO 15189 is a globally recognized quality standard for assuring the competence of medical laboratories and also ensures that laboratories maintain the same high standards of quality between countries.
STATE-OF-THE-ART ACCURACY
Advanced technology
The neoBona bioinformatics software employs an advanced algorithm that integrates multiple quality parameters including the sequencing depth for each chromosome, the content of each chromosome, the estimated fetal fraction and cfDNA fragment size to calculate the risk of aneuploidy. In this way, fetal fraction is no longer a constraint if the sequencing quality is adequate, allowing the generation of reliable results even at low fetal fraction.
Cirigliano V, Ordonez E, Rueda L, Syngelaki A, Nicolaides KH. Performance evaluation of the NeoBona test, a new paired-end massive parallel shotgun sequencing approach for cfDNA based aneuploidy screening. Ultrasound in Obstetrics & Gynecology. DOI:10.1002/uog.17386.
Genetic counselling and confirmation of an abnormal result
In case of a result compatible with an anomaly, our genetic specialists are available for expert support to the clinician and/or the patient (services may vary between countries).neoBona, like all NIPT, is a screening test and any abnormal result must be confirmed by prenatal diagnosis prior to any medical intervention.
SYNLAB'S COMPREHENSIVE SERVICE INCLUDES:
- Genetic consultation to the specialist (pre- and post-test) by our experts in prenatal and laboratory genetics
- Genetic counselling to patients (availability varies between countries)
- Access to SYNLAB'S comprehensive portfolio of genetic and non-genetic diagnostic services.
Why choose neoBona?
- neoBona is the most sensitive non-invasive screening method for trisomy 21, 18 and 13
- DIFFERENT TESTING OPTIONS taking into account the individual needs of each pregnancy
- Very low failure rate even at low fetal fraction (0.8% of redraws, <0.1% of test failures; SYNLAB internal data 2025)
- From the 10th WEEK OF PREGNANCY onwards (10 weeks + 0 days amenorrhea)
- Suitable after ASSISTED REPRODUCTION cases, including IVF with sperm or egg donation
- Suitable for TWIN PREGNANCIES, including cases of vanishing twins
- Results available in MAXIMUM 5 WORKING DAYS after the sample's arrival at the laboratory
- INCLUDES FETAL FRACTION, quantified with high accuracy thanks to innovative paired-end sequencing technology
- Performed exclusively in ISO15189-accredited laboratories
- Complete workflow is IVDR-certified
- CONSULTATION and SUPPORT available from our genetic experts
- Extensive NETWORK OF CENTRESwhere the test can be carried out